LeMaitre Vascular (NASDAQ:LMAT) Earns Outperform Rating from Barrington Research

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “outperform” rating reaffirmed by equities researchers at Barrington Research in a research note issued on Friday, Benzinga reports. They currently have a $92.00 target price on the medical instruments supplier’s stock. Barrington Research’s price target would suggest a potential upside of 1.94% from the stock’s previous close.

LMAT has been the topic of a number of other research reports. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Lake Street Capital started coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $94.40.

LeMaitre Vascular Stock Up 0.1 %

LeMaitre Vascular stock traded up $0.07 during midday trading on Friday, reaching $90.25. The company’s stock had a trading volume of 39,422 shares, compared to its average volume of 123,707. The business has a 50-day simple moving average of $86.76 and a 200-day simple moving average of $77.84. The company has a market cap of $2.03 billion, a P/E ratio of 59.77, a P/E/G ratio of 2.28 and a beta of 0.88. LeMaitre Vascular has a fifty-two week low of $44.27 and a fifty-two week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.37 EPS. As a group, equities analysts forecast that LeMaitre Vascular will post 1.85 earnings per share for the current year.

Insider Activity

In other news, CEO George W. Lemaitre sold 12,976 shares of LeMaitre Vascular stock in a transaction on Friday, July 12th. The stock was sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the completion of the transaction, the chief executive officer now owns 1,985,358 shares of the company’s stock, valued at approximately $170,879,763.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 12,976 shares of LeMaitre Vascular stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares of the company’s stock, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. Insiders sold a total of 43,251 shares of company stock worth $3,714,994 over the last 90 days. 10.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently modified their holdings of LMAT. CANADA LIFE ASSURANCE Co boosted its position in LeMaitre Vascular by 44.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after acquiring an additional 6,875 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after purchasing an additional 6,669 shares during the last quarter. Ranger Investment Management L.P. grew its position in shares of LeMaitre Vascular by 1.5% in the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after purchasing an additional 13,681 shares during the period. Congress Asset Management Co. MA increased its stake in LeMaitre Vascular by 12.0% in the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after purchasing an additional 71,411 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in LeMaitre Vascular by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.